Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Adults With Coronary Atherosclerosis
Conditions
Interventions
YN001/Placebo 40mg
YN001/Placebo 20mg
+1 more
Locations
13
China
Anhui Provincial Hospital
Hefei, Anhui, China
Anzhen Hospital
Beijing, Beijing Municipality, China
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Start Date
April 30, 2026
Primary Completion Date
July 31, 2027
Completion Date
March 31, 2029
Last Updated
April 9, 2026
NCT06863155
NCT01399385
NCT06779630
NCT00353782
NCT05461729
NCT07241390
Lead Sponsor
Beijing Inno Medicine Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions